Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer

Cancer

Volumn 120, Issue 23, 2014, Pages 3642-3650

  Daskivich, Timothy J ^a   Lai, Julie ^b   Dick, Andrew W ^b   Setodji, Claude M ^b   Hanley, Janet M ^b   Litwin, Mark S ^a,b,c   Saigal, Christopher ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RAND CORPORATION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Comorbidity; Life expectancy; Outcomes; Prostate adenocarcinoma; Survival

Indexed keywords

AGE; AGED; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; EARLY CANCER; GLEASON SCORE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROBABILITY; PROSTATE CANCER; PROSTATECTOMY; SAMPLE SIZE; VERY ELDERLY; ADENOCARCINOMA; MEDICARE; PATHOLOGY; PATIENT SELECTION; PROSTATE; PROSTATIC NEOPLASMS; RADIOTHERAPY; RETROSPECTIVE STUDY; SURGERY; UNITED STATES;

ADENOCARCINOMA; AGE FACTORS; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; COHORT STUDIES; COMORBIDITY; HUMANS; LIFE EXPECTANCY; MALE; MEDICARE; NEOPLASM STAGING; PATIENT SELECTION; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RETROSPECTIVE STUDIES; SEER PROGRAM; UNITED STATES;

EID: 84912569792     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28926     Document Type: Article

References (28)

1. Tewari A, Johnson CC, Divine G, et al. Long-term survival probability in men with clinically localized prostate cancer: a case-control, propensity modeling study stratified by race, age, treatment and comorbidities. J Urol. 2004; 171:1513-1519.
2. Daskivich TJ, Chamie K, Kwan L., et al. Comorbidity and competing risks for mortality in men with prostate cancer. Cancer. 2011; 20: 4642-4650.
3. Albertsen PC, Moore DF, Shih W, Lin Y., Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011; 29:1335-1341.
4. Berglund A, Garmo H, Tishelman C., Holmberg L, Stattin P, Lambe M. Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden. J Urol. 2011; 18:833-839.
5. Daskivich TJ, Kang-Hsien, F, Koyama T, et al. Impact of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer. Ann Intern Med. 2013; 158:709-717.
6. Lu-Yao GL, Albertsen PC, Moore DF. Outcomes of localized prostate cancer following conservative management. JAMA. 2009; 302: 1202-1209.
7. Klotz L, Zhang L, Lam A., Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010; 28:126-131.
8. Gore JL, Kwan L, Lee S.P., Reiter RE, Litwin MS. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer. J Natl Cancer Inst. 2009; 101:888-892.
9. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008; 358:1250-1261.
10. Resnick MJ, Koyama T, Fan K.H., et al. Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med. 2013; 368:436-445.
11. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177:2106-2131.
12. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010; 8:162-200.
13. Heidenreich A, Bellmunt J, Bolla M., et al. EAU Guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localized disease. Eur Urol. 2011; 59:61-71.
14. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010; 28:1117-1123.
15. Miller DC, Gruber SB, Hollenbeck B.K., Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006; 98:1134-1141.
16. Konety BR, Cowan JE, Carroll P.R., and the CaPSURE Investigators. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008; 179: 1797-1803.
17. Daskivich TJ, Chamie K, Kwan L., et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011; 117:2058-2066.
18. Roberts CB, Albertsen PC, Shao Y.H., et al. Patterns and correlates of prostate cancer treatment in older men. Am J Med. 2011; 124: 235-243.
19. Charlson ME, Pompei P, Ales K.L., MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40:373-383.
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45:613-619.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94:496-509.
22. Bill-Axelson A, Holmberg L, Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011; 364:1708-1717.
23. Saigal CS, Gore JL, Krupski T.L., Hanley J., Schonlau M, Litwin MS, and the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007; 110:1493-1500.
24. Tsai HK, D'Amico AV, Sadetsky N, Chen M.H., Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007; 99:1516-1524.
25. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009; 302:1685-1692.
26. Han PK, Klein WM, Lehman T.C., Massett H., Lee SC, Freedman AN. Laypersons' responses to the communication of uncertainty regarding cancer risk estimates. Med Decis Making. 2009; 29: 391-403.
27. Klabunde CN, Harlan LC, Warren JL. Data sources for measuring comorbidity: a comparison of hospital records and Medicare claims for cancer patients. Med Care. 2006; 44:921-928.
28. D'Amico AV, Whittington R, Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280:969-974.